Teclistamab Plus Daratumumab Cut Myeloma Death Risk
A study shows this two-drug combination may significantly improve survival outcomes for patients with relapsed multiple myeloma.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust new medical combination therapies to be safer than established treatment protocols?
A post hoc analysis of the phase 3 MajesTEC-3 trial found that the combination of teclistamab and daratumumab reduced the hazard of death by 78 percent for patients with relapsed or refractory multiple myeloma. The survival benefit appears to take effect after the 10-month mark compared to traditional treatment regimens.
Why it matters
This survival advantage is primarily driven by a significant reduction in disease progression among patients whose cancer has returned after initial therapy. These findings support using this combination as a potential new standard of care in the second-line setting.
The MajesTEC-3 trial analyzed outcomes in patients with relapsed or refractory multiple myeloma, observing a 78% reduction in death hazard after 10 months. Non-relapse mortality rates were comparable at 36 months, with the Tec-Dara arm at 10.2% compared to 9.0% in the control group.
The players
University of Alabama at Birmingham
This academic medical center serves as the home institution for the lead investigator of the MajesTEC-3 trial.
The details
The treatment works by combining teclistamab, a bispecific T-cell engager, with daratumumab, a monoclonal antibody, to target and destroy malignant plasma cells. To ensure patient safety, clinicians implemented standardized protocols including infection prophylaxis and universal immunoglobulin replacement to manage risks associated with the dual-therapy approach.
Timeline
Survival curves began to diverge in favor of the combination regimen starting at month 10.
Non-relapse mortality was evaluated at the 36-month follow-up period.
Health Landscape
The MajesTEC-3 trial represents an evolving strategy in oncology that moves toward combining multiple targeted therapies to combat relapsed disease. This development advances the current standard of care by demonstrating how aggressive, multi-agent regimens can effectively slow progression.
Patients currently undergoing treatment for relapsed or refractory multiple myeloma should discuss these findings with their oncologist to see how new standard-of-care data might inform their ongoing therapy plan. It is important to ask about how infection management protocols are integrated into these regimens.
The takeaway
The combination of teclistamab and daratumumab has shown a substantial reduction in the risk of death for specific myeloma patients. If you or a loved one are managing this condition, speak with your physician about whether this clinical trial data aligns with your current or future treatment options.
Further reading
For more information on current treatment trends for blood-related malignancies, visit our Cancer section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust new medical combination therapies to be safer than established treatment protocols?
